Risperidone and Social Outcome in Schizophrenia: A One Year Follow-up Study
DOI:
https://doi.org/10.61841/kfcjm119Keywords:
Risperidone,, social outcome, psychosocial, outcome.Abstract
Risperidone has been found to be effective in the management of schizophrenia across various studies. Most of these studies have looked at the clinical outcomes in patients with schizophrenia. The emphasis has always been on improvement in clinical features is usually primarily assessed by various rating scales. Most of these studies are of 8-12 weeks duration and report short-term outcomes. One should also assess the improvement on various psychosocial measures as clinical improvement may not give the clear picture of recovery. It is also important to look at the long-term outcome in schizoprenia. So the present study was envisaged with the intention to study the clinical as well psychosocial outcome at the end of one year in patients of schizophrenia on Risperidone. 50 consecutive patients of schizophrenia, diagnosed as per the DSM-IV criteria, fulfilling the selection criteria were followed-up and treated with Risperidone over a period of one year. Improvement was assessed using Positive and Negative Symptom Scale (PANSS), Clinical Global Improvement – Severity (CGI-S) and seven psychosocial parameters viz. social functioning, productivity, economic independence, education, suicidality, re-hospitalization and exacerbation. Predefined operational criteria were used to rate the patients on these seven psychosocial parameters. A statistically significant improvement was noticed with Risperidone therapy on PANSS and CGIS at the end of study period of one year. This was associated with a clinically significant improvement on all the various psychosocial parameters. A significant improvement was observed on clinical as well as psychosocial parameters in the patients of schizophrenia over a period of one year with Risperidone therapy.
Downloads
References
Awad, A.G., & Voruganti, L.N. (2004). Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs, 18(13), 877-893.
Eberhard, J., Levander, S., & Lindstrom, E. (2009). Remission in schizophrenia : analysis in a naturalistic setting. Comprehensive Psychiatry, 50(3), 200-208.
Emsley, R., & Oosthuizen, P. (2004). Evidence based pharmacotherapy for schizophrenia. International Journal of Neuropsychopharmacology, 7(2), 219-238.
Fiszdon, J.M., & Reddy, L.F. (2012). Review of social cognitive treatments for psychosis. Clinical Psychology Review, 32(8), 724-740.
Guo, X., Zhnag, Z., Zhai, J., & Early stage Schizophrenia Outcome Study Investigators. (2012). Effects of antipsychotic medication on quality of life and psychosocial functioning in patients with early stage schizophrenia : a one year follow up naturalistic study. Comprehensive Psychiatry, 53(7), 1006-1012.
Haro, J.M., & Salvador-Carulla, L. (2006). The SOHO (Schizophrenia Outpatient Health Outcome) study : implications for the treatment of schizophrenia. CNS Drugs, 20(4), 293-301.
Lin, A., Wood, S.J., & Yung, A.R. (2013). Measuring psychosocial outcome is good. Current Opinion in Psychiatry, 26(2), 138-143.
Ritsner, M., Gibel, A., Perelroyzen, G., Kurs, R., Jabarin, M., & Ratner, Y. (2004). Quality of life outcomes of risperidone, olanzapine and typical antipsychotics among schizophrenia patients treated in routine clinical practice : a naturalistic comparative study. Journal of Clinical Psychopharmacology, 24(6), 582-591.
McGrath, B.M., & Tempier, R.P. (2005). Patients’ opinions about olanzapine and risperidone after long term treatment : results from a cross sectional survey. Pharmacopsychiatry 2005; 38(4): 147-157.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
